Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date

References

• AbbinkEJDe GraafJDe HaanJHEffects of pioglitazone in familial combined hyperlipidaemiaJ Intern Med20062591071616336518
   PubMed Web of Science ®Google Scholar
• Adult Treatment Panel IIIExpert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adultsJAMA200128524869711368702
   PubMed Web of Science ®Google Scholar
• Aguilar SalinasCAZamoraMGomez-DiazRAFamilial combined hyperlipidemia: controversial aspects of its diagnosis and pathogenesisSemin Vasc Med20044203915478042
   PubMedGoogle Scholar
• AllayeeHKrassKLPajukantaPLocus for elevated apolipoprotein B levels on Chromosome 1p31 in families with familial combined hyperlipidemiaCirc Res2002909263111988495
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of Medical Care in Diabetes – 2006Diab Care200629S1S4S42
   PubMedGoogle Scholar
• AouizeratBEAllayeeHCantorRMLinkage of a candidate gene locus to familial combined hyperlipidemia: lecithin:cholesterol acyltransferase on 16qArterioscler Thromb Vasc Biol1999192730610559018
   PubMed Web of Science ®Google Scholar
• ArcaMNatoliSMichelettaFIncreased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapyFree Radic Biol Med20074269870517291993
   PubMed Web of Science ®Google Scholar
• AustinMABrunzellJFitchWLInheritance of LDL subclass patterns in familial combined hyperlipidemiaArteriosclerosis199010520302369363
   PubMedGoogle Scholar
• AustinMAMcKnightBEdwardsKLCardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective studyCirculation200010127778210859281
   PubMed Web of Science ®Google Scholar
• AyyobiAFBrunzellJDLipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemiaAm J Cardiol20039227J33J
   PubMed Web of Science ®Google Scholar
• AyyobiAFMcGladderySHMcNeelyMJSmall, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemiaArterioscler Thromb Vasc Biol20032312899412750118
   PubMed Web of Science ®Google Scholar
• BadziochMDIgoRPJrGagnonFLow-density lipoprotein particle size loci in familial combined hyperlipidemia: evidence for multiple loci from a genome scanArterioscler Thromb Vasc Biol20042419425015331429
   PubMed Web of Science ®Google Scholar
• BaysHSteinEAPharmacotherapy for dyslipidaemia – current therapies and future agentsExpert Opin Pharmacother2003419013814596646
   PubMed Web of Science ®Google Scholar
• Blanco-ColioLMMartin-VenturaJLSolJMDecreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatinJ Am Coll Cardiol20044311889415063428
   PubMed Web of Science ®Google Scholar
• BredieSJWesterveldHTKnipscheerHCEffects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemiaNeth J Med19964959678824106
   PubMed Web of Science ®Google Scholar
• CalabresiLVillaBCanavesiMAn omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemiaMetabolism200453153814767865
   PubMed Web of Science ®Google Scholar
• CampagnaFMontaliABaroniMGCommon variants in the lipoprotein lipase gene, but not those in the insulin receptor substrate-1, the beta3-adrenergic receptor, and the intestinal fatty acid binding protein-2 genes, influence the lipid phenotypic expression in familial combined hyperlipidemiaMetabolism200251129830512370850
   PubMed Web of Science ®Google Scholar
• CiceroAFGMartiniCNativioVAssociation between lipidic phenotype variability and CHD/CVD in a large rural population: the Brisighella StudyAtherosclerosis2000151105
   Google Scholar
• CiceroAFGPanourgiaMPLinarelloSSerum lipoprotein(a) levels in a large sample of subjects affected by familial combined hyperlipoproteinemia (FCH) and in general populationJ Cardiovasc Risk2003101495112668913
   PubMedGoogle Scholar
• CiceroFGGalettiCMartiniCVariability of the lipidic plasmatic phenotypes prevalence in a population and diagnosis of FCH: The Brisighella Heart StudyAtherosclerosis1999144S1139
   Google Scholar
• CiveiraFFor the International Panel on Management of Familial HypercholesterolemiaGuidelines for the diagnosis and management of heterozygous familial hypercholesterolemiaAtherosclerosis2004173556815177124
   PubMed Web of Science ®Google Scholar
• CoonHMyersRHBoreckiIBReplication of linkage of familial combined hyperlipidemia to chromosome 1q with additional heterogeneous effect of apolipoprotein A-I/C-III/A-IV locus: the NHLBI family heart studyArterioscler Thromb Vasc Biol20002022758011031215
   PubMed Web of Science ®Google Scholar
• CorellaDOrdovasJMSingle nucleotide polymorphisms that influence lipid metabolism: Interaction with dietary factorsAnnu Rev Nutr253419016011471
   PubMed Web of Science ®Google Scholar
• de BruinTWGeorgievaAMBrouwersMCRadiological evidence of nonalcoholic fatty liver disease in familial combined hyperlipidemiaAm J Med2004116847915178501
   PubMed Web of Science ®Google Scholar
• De BruinTWACastro CabezasMDallinga-YhieGBetteridgeDJFamilial Combined Hyperlipidaemia – do we understand the pathophysiology and genetics?Lipids: current perspectives1996LondonMartin Dunitzp1019
   Google Scholar
• de GraafJvan der VleutenGStalenhoefAFDiagnostic criteria in relation to the pathogenesis of familial combined hyperlipidemiaSemin Vasc Med200442294015630632
   PubMedGoogle Scholar
• de GraafJvan der VleutenGMter AvestEHigh plasma level of remnant-like particles cholesterol in familial combined hyperlipidemiaJ Clin Endocrinol Metab20079212697517227806
   PubMed Web of Science ®Google Scholar
• del Rincon JareroJPAguilar-SalinasCAGuillen-PinedaLELack of agreement between the plasma lipid-based criteria and apoprotein B for the diagnosis of familial combined hyperlipidemia in members of familial combined hyperlipidemia kindredsMetabolism2002512182411833052
   PubMed Web of Science ®Google Scholar
• DelawiDMeijssenSCastro CabezasMIntra-individual variations of fasting plasma lipids, apolipoproteins and postprandial lipemia in familial combined hyperlipidemia compared to controlsClin Chim Acta20033281394512559610
   PubMed Web of Science ®Google Scholar
• DemackerPNVeerkampMJBredieSJComparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemiaAtherosclerosis20001534839011164438
   PubMed Web of Science ®Google Scholar
• DurringtonPDyslipidaemiaLancet20033627173112957096
   PubMed Web of Science ®Google Scholar
• Eichenbaum-VolineSOlivierMJonesELLinkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemiaArterioscler Thromb Vasc Biol2004241677414551155
   PubMed Web of Science ®Google Scholar
• ElamMBHunninghakeDBDavisKBEffect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT trial – a randomized trialJAMA200028412637010979113
   PubMed Web of Science ®Google Scholar
• ElbeinSCHoffmanMDTengKA genome-wide search for type 2 diabetes susceptibility genes in Utah CaucasiansDiabetes19994811758210331426
   PubMed Web of Science ®Google Scholar
• EvansKBurdgeGCWoottonSATissue-specific stable isotope measurements of postprandial lipid metabolism in familial combined hyperlipidaemiaAtherosclerosis2007 Epub ahead of print
   Web of Science ®Google Scholar
• ForsterLFStewartGBedfordDInfluence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with the low VLDL and LDL fractional clearance ratesAtherosclerosis20021641294512119202
   PubMed Web of Science ®Google Scholar
• GaddiACiceroAFGNascettiSOn behalf of the Italian Study Group for the study of Dysmetabolic Diseases and AtherosclerosisCerebrovascular disease in Italy and Europe: it is necessary to prevent a “pandemia”Gerontology200349697912574667
   PubMed Web of Science ®Google Scholar
• GaddiAGalettiCPauciulloPOn behalf of the Committee of experts of the Atherosclerosis and Dysmetabolic Disorders Study GroupFamilial combined hyperlipoproteinemia: expert panel position on diagnostic criteria for clinical practiceNutr Metab Cardiovasc Dis199993041110765523
   PubMed Web of Science ®Google Scholar
• GaddiAVCiceroAFGMetabolic syndromes: diagnosis, prognosis, therapyBologna2006ItalyEsculapio Ed14552
   Google Scholar
• GeorgievaAMvan GreevenbroekMMKraussRMSubclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotypeArterioscler Thromb Vasc Biol200424744914751815
   PubMed Web of Science ®Google Scholar
• GoldsteinJLSchrottHGHazzardWRHyperlipidemia in coronary artery disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemiaJ Clin Invest1973521544684718953
   PubMed Web of Science ®Google Scholar
• GreenRMNASH – hepatic metabolism and not simply the metabolic syndromeHepatology200338141712829980
   PubMed Web of Science ®Google Scholar
• GrundySMVegaGLYuanZEffectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)Am J Cardiol200595462815695129
   PubMed Web of Science ®Google Scholar
• GrundySMVegaGLYuanZEffectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)Am J Cardiol200595462815695129
   PubMed Web of Science ®Google Scholar
• HashemAChiMTFriedmanCPMedical errors as a result of specializationJ Biomed Inform20033661914552847
   PubMed Web of Science ®Google Scholar
• HokansonJEAustinMAZambonAPlasma triglyceride and LDL heterogeneity in familial combined HyperlipidemiaArterioscler Thromb199313427348443147
   PubMedGoogle Scholar
• HopkinsPNHeissGEllisonRCCoronary Artery Disease Risk in Familial Combined Hyperlipidemia and Familial Hypertriglyceridemia. A Case-Control Comparison From the National Heart, Lung, and Blood Institute Family Heart StudyCirculation20031085192312847072
   PubMed Web of Science ®Google Scholar
• [IAS] International Atherosclerosis SocietyHarmonized Clinical Guidelines on Prevention of Atherosclerotic Vascular DiseaseIAS2003
   Google Scholar
• InsuaAMassariFRodriguez MoncalvoJJFenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover studyEndocr Pract200289610111942772
   PubMedGoogle Scholar
• IwataFOkadaTKuromoriYScreening for familial combined hyperlipidemia in children using lipid phenotypesJ Atheroscler Thromb20031029930314718747
   PubMedGoogle Scholar
• JeuLChengJWPharmacology and therapeutics of ezetimibe (SCH 58235:a cholesterol-absorption inhibitorClin Ther20032523528714604738
   PubMed Web of Science ®Google Scholar
• KaneJPHavelRJScriverCRBeaudetALSlyWValleDDisorders of biogenesis and secretion of lipoproteins containing the B apolipoproteinsThe metabolic basis of inherited disease1989New YorkMcGraw-Hill Inc.112964
   Google Scholar
• KarasekDVaverkovaHHalenkaMBrachial endothelial function in subjects with familial combined hyperlipidemia and its relationships to carotid artery intima-media thicknessInt Angiol2006254182617164751
   PubMed Web of Science ®Google Scholar
• KeulenETKruijshoopMSchaperNCIncreased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein BArterioscler Thromb Vasc Biol200222283811834529
   PubMed Web of Science ®Google Scholar
• KissebahAHAlfarsiSEvansDJLDL metabolism in familial combined hyperlipidemia. Mechanism of the multiple lipoprotein phenotypic expressionArteriosclerosis19844614246508636
   PubMedGoogle Scholar
• KohKKQuonMJHanSHAdditive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemiaJ Am Coll Cardiol20054516495315893182
   PubMed Web of Science ®Google Scholar
• KoprovicovaJKollarJPetrasovaDNutrition, body weight and deterioration of familial combined hyperlipidemiaColl Antropol2006307778217243549
   PubMedGoogle Scholar
• KuromoriYOkadaTIwataFFamilial combined hyperlipidemia (FCH) in children: the significance of early development of hyperapoB lipoproteinemia, obesity and agingJ Atheroscler Thromb200293142012560593
   PubMedGoogle Scholar
• KwiterovichPOHyperapoB: a pleiotropic phenotype characterized by dense low density lipoproteins and associated coronary artery diseaseClin Chem199834B71B73042202
   PubMedGoogle Scholar
• LenziSBucciACrepaldiGThe CNR program of preventive medicine – SP4 Objective 44. Non-invasive techniques for the evaluation of atherosclerotic plaque progression or regressionMonogr Atheroscler19861483903526133
   PubMedGoogle Scholar
• LiuMLYlitaloKNuotioIAssociation between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia familiesStroke20023312556011988600
   PubMed Web of Science ®Google Scholar
• LiuMLYlitaloKVakkilainenJSusceptibility of LDL to oxidation in vitro and antioxidant capacity in familial combined hyperlipidemia: comparison of patients with different lipid phenotypesAnn Med200234485412014434
   PubMed Web of Science ®Google Scholar
• MancusoGLa ReginaGBagnoliM“Normolipemic” tendinous and tuberous xanthomatosisDermatology199619327328864614
   PubMed Web of Science ®Google Scholar
• MeijssenSDerksenRJBilecenSIn vivo modulation of plasma free fatty acids in patients with Familial Combined Hyperlipidemia using lipid-lowering medicationJ Clin Endocrinol Metab2002a8715768011932285
   PubMed Web of Science ®Google Scholar
• MeijssenSvan DijkHVerseydenCDelayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemiaArterioscler Thromb Vasc Biol2002b228111612006395
   PubMed Web of Science ®Google Scholar
• NHANES GroupPlan and Operation of the Third National Health and Nutrition Examination Survey, 1988–94. Series 1: programs and collection proceduresVital Health Stat1994321407
   Google Scholar
• O’LearyDHPolakJFIntima-media thickness: a tool for atherosclerosis imaging and event predictionAm J Cardiol20029018L21L
   PubMed Web of Science ®Google Scholar
• PajukantaPLiljaHESingheimerJSFamilial Combined hyperlipidemia is associated with upstream transcription factor 1 (USF 1)Nat Gen2004363716
   PubMed Web of Science ®Google Scholar
• PajukantaPNuotioITerwilligerJDLinkage of familial combined hyperlipidaemia to chromosome 1q21q23Nat Genet199818369739537421
   PubMed Web of Science ®Google Scholar
• PeiWBaronHMuller-MyhsokBSupport for the linkage of familial combined hyperlipidemia to chromosome 1q21–q23 in Chinese and German familiesClin Genet200057293410733233
   PubMed Web of Science ®Google Scholar
• PihlajamakiJKarjalainenLKarhapaaPG-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemiaArterioscler Thromb Vasc Biol20002017899510894818
   PubMed Web of Science ®Google Scholar
• PitkanenOPNuutilaPRaitakariOTCoronary flow reserve in young men with familial combined hyperlipidemiaCirculation19999916788410190876
   PubMed Web of Science ®Google Scholar
• RizzoMBerneisKLow-density lipoprotein size and cardiovascular risk assessmentQJM20069911416371404
   PubMed Web of Science ®Google Scholar
• SirtoriCRCalabresiLPisciottaLEffect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatinNutr Metab Cardiovasc Dis200515475515871851
   PubMed Web of Science ®Google Scholar
• SkoumasIMasouraCPitsavosCEvidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemiaInt J Cardiol2006 Epub ahead of print
   Web of Science ®Google Scholar
• SnidermanADCastro CabezasMRibaltaJA proposal to redefine familial combined hyperlipidaemia – Third workshop on FCH held in Barcelona from 3 to 5 May 2001, during the Scientific Sessions of the European Society for Clinical InvestigationEur J Clin Invest20023271311895451
   PubMed Web of Science ®Google Scholar
• SnidermanADRibaltaJCastro CabezasMHow should FCH be defined and how should we think about its metabolic bases?Nutr Metab Cardiovasc Dis2001112597311831111
   PubMed Web of Science ®Google Scholar
• SoroAJauhiainenMEhnholmCDeterminants of low HDL levels in familial combined hyperlipidemiaJ Lipid Res20034415364412777471
   PubMed Web of Science ®Google Scholar
• StalenhoefAFInteraction between genes and environment in inherited lipid disorders determines clinical presentationCardiovasc Drugs Ther200216271212659084
   PubMed Web of Science ®Google Scholar
• SvegerTNordborgKApolipoprotein B as a marker of familial hyperlipoproteinemiaJ Atheroscler Thromb2004112869215557711
   PubMedGoogle Scholar
• TatoFKellerCWolframGEffects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemiaClin Investig19937131418
   PubMedGoogle Scholar
• ter AvestEAbbinkEJHolewijnSEffects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH)Curr Med Res Opin20052114697616197666
   PubMed Web of Science ®Google Scholar
• ter AvestESnidermanADBredieSJEffect of aging and obesity on the expression of dyslipidaemia in children from families with familial combined hyperlipidaemiaClin Sci2007a112131917054424
   PubMed Web of Science ®Google Scholar
• ter AvestEHolewijnSvan TitsLJEndothelial function in familial combined hyperlipidaemiaEur J Clin Invest2007b37381917461984
   PubMed Web of Science ®Google Scholar
• ter AvestEHolewijnSBredieSJPulse wave velocity in familial combined hyperlipidemiaAm J Hypertens2007c20263917324737
   PubMed Web of Science ®Google Scholar
• ThomasELPotterETosiIPioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: Relation to liver, muscle and regional body fat contentAtherosclerosis2007 Epub ahead of print
   Google Scholar
• VakkilainenJPajukantaPCantorRMGenetic influences contributing to LDL particle size in familial combined hyperlipidaemiaEur J Hum Genet2002105475212173032
   PubMed Web of Science ®Google Scholar
• van der KallenCJVoors-PetteCde BruinTWAbdominal obesity and expression of familial combined hyperlipidemiaObes Res20041220546115687407
   PubMedGoogle Scholar
• van der VleutenGMvan TitsLJden HeijerMDecreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profileJ Lipid Res2005a46239840416106049
   PubMed Web of Science ®Google Scholar
• van der VleutenGMVeerkampMJvan TitsLJElevated leptin levels in subjects with familial combined hyperlipidemia are associated with the increased risk for CVDAtherosclerosis2005b1833556016285998
   PubMed Web of Science ®Google Scholar
• VeerkampMJde GraafJBredieSJHDiagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families. Results of a 5-Year Follow-Up StudyArterioscler Thromb Vasc Biol2002222748211834528
   PubMed Web of Science ®Google Scholar
• VeerkampMJde GraafJHendriksJCMNormogram to diagnose Familial Combined Hyperlipidemia on the basis of results of a 5-year follow-up studyCirculation2004109298792
   Web of Science ®Google Scholar
• VeerkampMJde GraafJStalenhoefAFRole of insulin resistance in familial combined hyperlipidemiaArterioscler Thromb Vasc Biol20052510263115731490
   PubMed Web of Science ®Google Scholar
• VenkatesanSCullenPPacyPStable isotopes show a direct relation between VLDL Apo B overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemiaArterioscler Thromb1983131110188318511
   PubMedGoogle Scholar
• VerseydenCMeijssenSCabezasMCEffects of atorvastatin on fasting plasma and marginated apolipoproteins B48 and B100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemiaJ Clin Endocrinol Metab2004895021915472200
   PubMed Web of Science ®Google Scholar
• VerseydenCMeijssenSCastro CabezasMPostprandial changes of apoB-100 and apoB-48 in TG rich lipoproteins in familial combined hyperlipidemiaJ Lipid Res2002432748011861669
   PubMed Web of Science ®Google Scholar
• WangTDChenWJLinJWEfficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profilesAtherosclerosis20031703152314612213
   PubMed Web of Science ®Google Scholar
• WilliamsKJPetrieABrociaRWLipoprotein lipase modulates net secretory output of apolipoprotein B in vitro: a possible pathophysiologic explanation for familial combined HyperlipidemiaJ Clin Invest199188130061918380
   PubMed Web of Science ®Google Scholar
• WiltshireSHattersleyATHitmanGAA genomewide scan for loci predisposing to type 2 diabetes in a UK population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1qAm J Hum Genet2001695536911484155
   PubMed Web of Science ®Google Scholar
• YlitaloKSyvanneMSalonenRCarotid artery intima-media thickness in Finnish families with familial combined hyperlipidemiaAtherosclerosis2002162171811947911
   PubMed Web of Science ®Google Scholar